+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07641036

Study of Dual-Target HER2 and CEACAM5 CAR-NK Cell Therapy for Advanced Biliary Tract Cancers After Prior Treatment

Led by Beijing Biotech · Updated on 2026-06-11

30

Participants Needed

1

Research Sites

83 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying EB-HC01, an off-the-shelf dual-target CAR-NK cell therapy designed to treat adults with unresectable or metastatic cholangiocarcinoma or other biliary tract cancers who have already received standard treatments. This phase 12 open-label study focuses on safety, dosing, and early effectiveness signals while selecting patients based on specific biomarkers, HER2 and CEACAM5, to better target the cancer cells. Participants receive reduced-intensity lymphodepletion with fludarabine and cyclophosphamide before getting EB-HC01 infusions intravenously on Days 0 and 7 of each 28-day cycle. The study has two parts Part A determines the recommended dose by testing different dose levels, and Part B further evaluates safety and preliminary anti-tumor activity at the chosen dose. Up to two cycles are allowed in dose escalation, and up to four cycles in expansion, depending on response and tolerability. During the study, participants undergo biomarker testing, blood sample collection to monitor CAR-NK cell persistence and cytokine levels, and imaging to measure tumor response. Researchers assess dose-limiting toxicities over 28 days and track adverse events for up to 12 months. They also evaluate tumor response, disease control, and survival outcomes over longer periods, with follow-up lasting up to 24 months. The total participation duration can extend up to nearly two years based on treatment and monitoring schedules.

CONDITIONS

Brief Title

Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

Research Team

S

Seni S Lu, Phd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here